Cemiplimab for locally advanced and metastatic basal cell carcinoma

Damsin, Thomas; Lebas, Eve; Marchal, Nathalie; Rorive, Andrée; Nikkels, Arjen F.

doi:10.1080/14737140.2022.2043748

Cited by 10 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cemiplimab, a fully human monoclonal antibody against the PD1 receptor, is an FDA-approved immune checkpoint inhibitor for treating locally advanced cutaneous squamous cell carcinoma (laSCC) and metastatic cutaneous squamous cell carcinoma (mSCC) not amenable to surgery or radiation therapy [ 106 ]. In February 2021, cemiplimab garnered FDA approval for treating locally-advanced and metastatic BCC, thereby providing HPI-refractory patients a second-line treatment option [ 106 , 107 ]. BCCs harbor a high mutational burden and are thus expected to respond well to broad anti-tumor immune activity, elicited by immune checkpoint inhibitors such as cemiplimab.…”

Section: Systemic Therapiesmentioning

confidence: 99%

Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma

Chen

Kim²,

Steele³

et al. 2022

Cancers

View full text Add to dashboard Cite

Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, and patient attributes determine the risk level and acceptable treatment options. Surgical options offer histologic confirmation of tumor clearance. Standard excision provides post-treatment histologic assessment, while Mohs micrographic surgery (MMS) provides complete margin assessment intraoperatively. Additional treatment options may be employed in the correct clinical context. Small and low-risk BCCs, broad field cancerization, locally-advanced disease, metastatic disease, cosmetic concerns, or morbidity with surgical approaches raise consideration of other treatment modalities. We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies.

show abstract

Section: Systemic Therapiesmentioning

confidence: 99%

Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma

Chen

Kim²,

Steele³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, HHI therapy is a first-line option for laBCC or mBCC [ 7 ]. Cemiplimab is indicated and recommended as a first-line after HHIs’ treatments, either when the HHI therapy becomes intolerable, or when the BCC progresses despite HHI treatment, or when the BCC is stable but does not improve after nine consecutive months of HHI therapy [ 159 ].…”

Section: Therapymentioning

confidence: 99%

Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma

Hoashi

Kanda

Saeki

2022

IJMS

View full text Add to dashboard Cite

Among human cutaneous malignancies, basal cell carcinoma is the most common. Solid advances in unveiling the molecular mechanisms of basal cell carcinoma have emerged in recent years. In Gorlin syndrome, which shows basal cell carcinoma predisposition, identification of the patched 1 gene (PTCH1) mutation was a dramatic breakthrough in understanding the carcinogenesis of basal cell carcinoma. PTCH1 plays a role in the hedgehog pathway, and dysregulations of this pathway are known to be crucial for the carcinogenesis of many types of cancers including sporadic as well as hereditary basal cell carcinoma. In this review, we summarize the clinical features, pathological features and hedgehog pathway as applied in basal cell carcinoma. Other crucial molecules, such as p53 and melanocortin-1 receptor are also discussed. Due to recent advances, therapeutic strategies based on the precise molecular mechanisms of basal cell carcinoma are emerging. Target therapies and biomarkers are also discussed.

show abstract

“…Nivolumab is now FDA‐approved for the treatment of several cancers including esophageal cancer, advanced non‐small cell lung cancer, melanoma, and colon cancer. Cimiplimab is FDA approved for treatment in advanced cSCC, locally advanced BCC, and non‐small‐cell lung carcinoma 39,42–46 …”

Section: Pd‐l1 In Cscc and Ici Immunotherapy Efficacymentioning

confidence: 99%

“…Cimiplimab is FDA approved for treatment in advanced cSCC, locally advanced BCC, and non-small-cell lung carcinoma. 39,[42][43][44][45][46] Regarding PD-L1-targeted immunotherapies, atezolizumab (Tecentirq) is approved for the treatment of lung cancer and urothelial carcinoma, triple-negative breast cancer, hepatocellular carcinoma, and melanoma, but not yet cSCC. 39 Avelumab is under investigation as part of a clinical trial targeting cSCC but is only currently approved for metastatic Merkel cell carcinoma and metastatic urothelial carcinoma.…”

Section: Pd-l1 In Cscc and Ici Immunotherapy Efficacymentioning

confidence: 99%

“…mAb PD-1 Pembrolizumab cSCC, HNSCC [39], [41], [42], [56], [68] Nivolumab cSCC NSCLC [39], [42], [43] Cemiplimab NSCLC, BCC, cSCC [39], [42], [44][45][46], [55], [60] PDL-1 Atezolizumab NSCLC [39], [40], [48] Avelumab cSCC [39], [47] Durvalumab cSCC NSCLC [39], [48][49][50], [69] Small molecule inhibitor PD -L1 CA-170 b Clinical trials for advanced solid tumors and lymphoma [70] IMMH-010 Clinical trials for advanced malignant solid tumors [71], [72] BMS-202 SCC3 lymphoma explants in mice [73][74][75][76][77], [81], [91] BMS-1001 In vitro only [78] BMS-1166 In vitro only [78] BMS −37 colon adenocarcinoma xenograft [79], [80] NP-19 Melanoma and hepatoma models [81] Fraxinellone Lung cancer xenograft model [82] […”

Section: Type Of Agentmentioning

confidence: 99%

See 1 more Smart Citation

Review: PD‐L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer

Vaishampayan

Curiel‐Lewandrowski

Dickinson

2022

Molecular Carcinogenesis

View full text Add to dashboard Cite

Recent advances in the understanding and targeting of immune checkpoints have led to great progress in immune therapies against many forms of cancer. While many types of immune checkpoints are currently targeted in the clinic, this review will focus on recent research implicating the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis as an emerging focus for the treatment of keratinocytic tumors. PD-L1 is of particular interest in nonmelanoma skin cancer (NMSC), as it is not only upregulated in these tumors but is stimulated by environmental ultraviolet exposure. This response may also make PD-L1 an excellent target for photochemoprevention using topically applied small molecule inhibitors.Here, we summarize recent investigations on PD-L1 expression and clinically relevant immune checkpoint inhibitor treatment in cutaneous squamous cell carcinoma, basal cell carcinoma, and head and neck squamous cell carcinoma, as well as small molecule agents targeting PD-L1 that may be useful for clinical development aiming at treatment or prevention of NMSC.

show abstract

Cemiplimab for locally advanced and metastatic basal cell carcinoma

Cited by 10 publications

References 45 publications

Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma

Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma

Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma

Review: PD‐L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer

Contact Info

Product

Resources

About